We are live on
!
Find out more
LPC
Lion Point Capital Portfolio holdings
AUM
$16.7M
1-Year Est. Return
119.35%
This Fund
S&P 500
This Quarter
Est. Return
-4.5%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$16.7M
AUM Growth
-$2.59M
(-13%)
Cap. Flow
-$492K
Cap. Flow
% of AUM
-2.94%
Top 10 Holdings %
Top 10 Hldgs %
54.62%
Holding
39
New
–
Increased
3
Reduced
–
Closed
4
Top Buys
| 1 |
Humacyte
HUMA
|
+$156K |
| 2 |
CMPS
Compass Pathways
CMPS
|
+$148K |
| 3 |
Milestone Pharmaceuticals
MIST
|
+$114K |
Top Sells
| 1 |
DAWN
Day One Biopharmaceuticals
DAWN
|
+$391K |
| 2 |
VTYX
Ventyx Biosciences
VTYX
|
+$375K |
| 3 |
Minerva Neurosciences
NERV
|
+$141K |
| 4 |
MRSN
Mersana Therapeutics
MRSN
|
+$2.89K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Seres Therapeutics
MCRB
$50.2M
| $280K | 1.67% |
31,570
| – | – |
|
27
Janux Therapeutics
JANX
$966M
| $264K | 1.58% |
19,000
| – | – |
|
28
uniQure
QURE
$2.71B
| $240K | 1.44% |
14,700
| – | – |
|
29
Regenxbio
RGNX
$579M
| $223K | 1.33% |
26,600
| – | – |
|
30
Azenta
AZTA
$1.23B
| $205K | 1.23% |
9,700
| – | – |
|
31
Innoviva
INVA
$1.64B
| $191K | 1.14% |
8,200
| – | – |
|
32
GH Research
GHRS
$2B
| $143K | 0.86% |
10,200
| – | – |
|
33
Arcutis Biotherapeutics
ARQT
$3.47B
| $124K | 0.74% |
5,250
| – | – |
|
|
IPHA
34
Innate Pharma
IPHA
$166M
| $104K | 0.62% |
81,151
| – | – |
|
|
SPRB
35
Spruce Biosciences
SPRB
$122M
| $65.3K | 0.39% |
1,000
| – | – |
|
|
DAWN
36
DELISTED
Day One Biopharmaceuticals
DAWN
| – | – |
-42,000
| Closed | -$391K |
|
|
MRSN
37
DELISTED
Mersana Therapeutics
MRSN
| – | – |
-100
| Closed | -$2.89K |
|
|
38
Minerva Neurosciences
NERV
$196M
| – | – |
-35,000
| Closed | -$141K |
|
|
VTYX
39
DELISTED
Ventyx Biosciences
VTYX
| – | – |
-41,500
| Closed | -$375K |
|
Similar funds
PA
PA
SR
SCTC
SRA
CP
B
CVV